Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Weight loss, Support group, Exercise, Atomoxetine
Eligibility Criteria
Inclusion Criteria: Schizophrenia or schizoaffective Disorder Taking olanzapine or clozapine for at least 6 months Weight gain of 7% over baseline or BMI greater than or equal to 27 Exclusion Criteria: Current treatment with methylphenidate, clonidine, tricyclic antidepressants, bupropion and venlafaxine Treatment with other medications known to cause weight gain unless weight stable on medication for 6 months Current treatment with other medications for weight loss unless weight stable for 6 months Mental Retardation Alcohol or Substance Dependence within the last 6 months Pregnancy Alcohol or Substance Abuse within the lat month Uncontrolled hypertension defined as a blood pressure exceeding 140/90 on three consecutive readings despite adequate treatment
Sites / Locations
- Maryland Psychiatric Research Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
active
Placebo
Atomoxetine titrated up to 120 mg/day by week 8 and continues at 120 mg/day through week 24. Diet support group, group counseling and exercise.
Placebo medication, diet support group, group counseling and exercise